Home Forums Marketplace Table of Contents Events Member List Site Map Register Mark Forums Read



Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.


CrystalGenomics Announces Positive Phase IIa Results For Osteoarthritis Study Of CG100649

Reply
Submit Thread >  Submit to Digg Submit to Reddit Submit to Furl Submit to Del.icio.us Submit to Google Submit to Yahoo! This Submit to Technorati Submit to StumbleUpon Submit to Spurl Submit to Netscape  < Submit Thread
 
Thread Tools Display Modes
  #1  
Old 23rd December 2008, 04:30 AM
RSSFeedBot RSSFeedBot is offline
I, Robot
 
About:
Join Date: Jul 2008
Posts: 3,061
Join Date: Jul 2008
Marketplace reputation 0% (0)
CPD Points: 1
Thanks: 0
Thanked 5 Times in 5 Posts
Default CrystalGenomics Announces Positive Phase IIa Results For Osteoarthritis Study Of CG100649

Podiatry Arena members do not see these ads
CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, CA) announced positive results from a Phase IIa osteoarthritis (OA) study of the efficacy and safety of a next-generation NSAID, CG100649. The CG100649 treatment group met the primary efficacy endpoint by demonstrating a clinically and statistically significant change in the WOMAC(TM) OA score from baseline to Day 21 (p=0.010) compared to placebo.

More...
Reply With Quote
Sponsored Links
Reply



Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
vB code is On
Smilies are On
[IMG] code is On
HTML code is On
Forum Jump

Translate This Page

Similar Threads
Thread Thread Starter Forum Replies Last Post
Forest Laboratories, Inc. And Cypress Bioscience, Inc. Announce Positive Results Of Phase III Study Of Milnacipran For The Management Of Fibromyalgia RSSFeedBot Latest Rheumatology News 0 9th December 2008 04:20 AM
Results From The First And Largest Collaborative Study Confirm Role Of Enbrel® In Psoriatic Arthritis RSSFeedBot Latest Rheumatology News 0 4th December 2008 09:40 AM
Non- Steroidal Combination Drug To Treat Psoriasis - Positive Phase 2b Results Showing Efficacy And Synergy DPS-101 RSSFeedBot Latest Dermatology News 0 4th November 2008 01:21 PM
BioCryst Reports Results From BCX-4208 Phase IIa Trial In Subjects With Psoriasis RSSFeedBot Latest Dermatology News 0 5th September 2008 06:01 AM


New To Site? Need Help?

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.


All times are GMT -7. The time now is 04:05 PM.